Lipocine raises $38m to advance testosterone portfolio
This article was originally published in Scrip
Executive Summary
Specialty pharma company Lipocine has raised $38m in a private placement of 6.3 million shares of its common stock, having just completed a reverse merger with shell company Marathon Bar Corp in order to list on the Over-The-Counter Bulletin Board (OTCBB).